- Home
- AIN vs IMCR Comparison
AIN vs IMCR Comparison
Compare AIN & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIN
- IMCR
- Stock Information
- Founded
- AIN 1895
- IMCR 2008
- Country
- AIN United States
- IMCR United Kingdom
- Employees
- AIN N/A
- IMCR N/A
- Industry
- AIN Textiles
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AIN Consumer Discretionary
- IMCR Health Care
- Exchange
- AIN Nasdaq
- IMCR Nasdaq
- Market Cap
- AIN 1.9B
- IMCR 1.7B
- IPO Year
- AIN 1987
- IMCR 2021
- Fundamental
- Price
- AIN $56.54
- IMCR $34.14
- Analyst Decision
- AIN Hold
- IMCR Buy
- Analyst Count
- AIN 5
- IMCR 9
- Target Price
- AIN $71.40
- IMCR $57.00
- AVG Volume (30 Days)
- AIN 306.4K
- IMCR 287.9K
- Earning Date
- AIN 10-29-2025
- IMCR 11-05-2025
- Dividend Yield
- AIN 1.91%
- IMCR N/A
- EPS Growth
- AIN N/A
- IMCR N/A
- EPS
- AIN 2.01
- IMCR N/A
- Revenue
- AIN $1,185,464,000.00
- IMCR $356,145,000.00
- Revenue This Year
- AIN N/A
- IMCR $29.71
- Revenue Next Year
- AIN $4.19
- IMCR $11.27
- P/E Ratio
- AIN $28.05
- IMCR N/A
- Revenue Growth
- AIN N/A
- IMCR 26.78
- 52 Week Low
- AIN $50.60
- IMCR $23.15
- 52 Week High
- AIN $88.13
- IMCR $39.33
- Technical
- Relative Strength Index (RSI)
- AIN N/A
- IMCR 49.47
- Support Level
- AIN N/A
- IMCR $33.79
- Resistance Level
- AIN N/A
- IMCR $37.00
- Average True Range (ATR)
- AIN 0.00
- IMCR 1.31
- MACD
- AIN 0.00
- IMCR -0.08
- Stochastic Oscillator
- AIN 0.00
- IMCR 39.51
About AIN Albany International Corporation
Albany International Corp is principally engaged in processing textiles and materials. The company consists of two business segments, the machine clothing segment, which produces and provides custom-designed fabrics and belts for the production in the paper, nonwovens, and other process industries; and the Albany engineered composites segment, which offers engineered composite parts for the aerospace and defensive industries. The machine clothing segment contributes to the majority of the company's total revenue. The company has an operation and generates revenue from the United States, Switzerland, Brazil, China, Mexico, France, and other areas.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.